HOME > 상세정보

상세정보

Cancer immunotherapy [electronic resource] : immune suppression and tumor growth

Cancer immunotherapy [electronic resource] : immune suppression and tumor growth

자료유형
E-Book(소장)
개인저자
Prendergast, George C. Jaffee, Elizabeth M.
서명 / 저자사항
Cancer immunotherapy [electronic resource] : immune suppression and tumor growth / edited by George Prendergast, Elizabeth M. Jaffee.
발행사항
Amsterdam ;   Boston :   Academic Press/Elsevier,   2007.  
형태사항
1 online resource (xiii, 409 p., [4] p. of plates) : ill. (some col.).
기타형태 저록
Print version:   Cancer immunotherapy.   Amsterdam ; Boston : Academic Press/Elsevier, 2007   9780123725516   0123725518   (211009) 000045782221  
ISBN
9780123725516 0123725518 9780080521855 (electronic bk.) 0080521851 (electronic bk.)
요약
There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease. * Offers a synthesis of concepts that are useful to cancer immunologists and pharmacologists, who tend to work in disparate fields with little cross-communication * Drs Prendergast and Jaffee are internationally recognized leaders in cancer biology and immunology who have created a unique synthesis of fundamental and applied concepts in this important new area of cancer research * Summarizes the latest insights into how immune escape defines an essential trait of cancer * Includes numerous illustrations including: how molecular-targeted therapeutic drugs or traditional chemotherapy can be combined with immunotherapy to improve anti-tumor efficacy; and how reversing immune suppression by the tumor can cause tumor regression.
일반주기
Title from e-Book title page.  
내용주기
Part I: Principles of Cancer Immunobiology -- Introduction -- Cancer Immunoediting: From Immune Surveillance to Immune Escape -- Immunosurveillance: Innate and Adaptive Anti-Tumor Immunity -- Cytokine Regulation of Immune Tolerance to Tumors -- Immunological Sculpting: Natural Killer Cell Receptors and Ligands -- Immune Escape: Immunosuppressive Networks -- Part II: Cancer Therapeutics -- Cytotoxic Chemotherapy in Clinical Treatment of Cancer -- Targeted Therapeutics in Cancer Treatment -- Concepts in Pharmacology and Toxicology -- Cancer Immunotherapy: Challenges and Opportunities -- Cancer Vaccines -- Part III: Targets and Tactics to Improve Cancer Immunotherapy By Defeating Immune Suppression -- Immunotherapy and Cancer Therapeutics: Why Partner? -- Immune Stimulatory Features of Classical Chemotherapy -- Dendritic Cells and Co-Inhibitory Molecules -- Regulatory T Cells in Tumor Immunity: Role of Toll-like Receptors -- Tumor-associated Macrophages in Cancer Growth and Progression -- Tumor-associated Myeloid-derived Suppressor Cells -- Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor Immune Escape -- IDO in Immune Escape: Regulation and Therapeutic Inhibition -- Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation -- Summary: Future Questions.
서지주기
Includes bibliographical references and index.
이용가능한 다른형태자료
Issued also as a book.  
일반주제명
Cancer --Immunotherapy. Antineoplastic agents --Therapeutic use. Tumors --Immunological aspects. Neoplasms --therapy. Antineoplastic Agents --therapeutic use. Immunotherapy --methods.
바로가기
ScienceDirect   URL
000 00000cam u2200205 a 4500
001 000045946665
005 20180712093751
006 m d
007 cr
008 070806s2007 ne af ob 001 0 eng d
020 ▼a 9780123725516
020 ▼a 0123725518
020 ▼a 9780080521855 (electronic bk.)
020 ▼a 0080521851 (electronic bk.)
035 ▼a (OCoLC)162574047 ▼z (OCoLC)179890848 ▼z (OCoLC)648246525 ▼z (OCoLC)916416304 ▼z (OCoLC)961620266 ▼z (OCoLC)962623335
040 ▼a OPELS ▼b eng ▼e pn ▼c OPELS ▼d OCLCQ ▼d N$T ▼d YDXCP ▼d IDEBK ▼d E7B ▼d OCLCQ ▼d ITD ▼d OCLCQ ▼d OCLCF ▼d OCLCQ ▼d CHVBK ▼d NLGGC ▼d OCLCQ ▼d ZZAND ▼d OCLCQ ▼d AZK ▼d LOA ▼d OCLCO ▼d JBG ▼d OCLCO ▼d OCLCA ▼d TOA ▼d OCLCO ▼d STF ▼d MOR ▼d PIFAG ▼d OCLCQ ▼d OCLCO ▼d OCLCA ▼d 211009
049 ▼a TEFA
050 0 0 ▼a RC271.I45 ▼b C363 2007
082 0 0 ▼a 616.99/4061 ▼2 23
084 ▼a 616.994061 ▼2 DDCK
090 ▼a 616.994061
245 0 0 ▼a Cancer immunotherapy ▼h [electronic resource] : ▼b immune suppression and tumor growth / ▼c edited by George Prendergast, Elizabeth M. Jaffee.
260 ▼a Amsterdam ; ▼a Boston : ▼b Academic Press/Elsevier, ▼c 2007.
300 ▼a 1 online resource (xiii, 409 p., [4] p. of plates) : ▼b ill. (some col.).
500 ▼a Title from e-Book title page.
504 ▼a Includes bibliographical references and index.
505 0 ▼a Part I: Principles of Cancer Immunobiology -- Introduction -- Cancer Immunoediting: From Immune Surveillance to Immune Escape -- Immunosurveillance: Innate and Adaptive Anti-Tumor Immunity -- Cytokine Regulation of Immune Tolerance to Tumors -- Immunological Sculpting: Natural Killer Cell Receptors and Ligands -- Immune Escape: Immunosuppressive Networks -- Part II: Cancer Therapeutics -- Cytotoxic Chemotherapy in Clinical Treatment of Cancer -- Targeted Therapeutics in Cancer Treatment -- Concepts in Pharmacology and Toxicology -- Cancer Immunotherapy: Challenges and Opportunities -- Cancer Vaccines -- Part III: Targets and Tactics to Improve Cancer Immunotherapy By Defeating Immune Suppression -- Immunotherapy and Cancer Therapeutics: Why Partner? -- Immune Stimulatory Features of Classical Chemotherapy -- Dendritic Cells and Co-Inhibitory Molecules -- Regulatory T Cells in Tumor Immunity: Role of Toll-like Receptors -- Tumor-associated Macrophages in Cancer Growth and Progression -- Tumor-associated Myeloid-derived Suppressor Cells -- Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor Immune Escape -- IDO in Immune Escape: Regulation and Therapeutic Inhibition -- Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation -- Summary: Future Questions.
505 0 ▼a Introduction / George C. Prendergast and Elizabeth M. Jaffee -- Cancer immunoediting : from immune surveillance to immune escape / Ryungsa Kim -- Immunosurveillance : innate and adaptive antitumor immunity / Masahisa Jinushi and Glenn Dranoff -- Cytokine regulation of immune tolerance to tumors / Ming O. Li and Richard A. Flavell -- Immunological sculpting : natural killer cell receptors and ligands / David A. Sallman and Julie Y. Djeu -- Immune escape : immunosuppressive networks / Shuang Wei, Alfred Chang, and Weiping Zou -- Cytotoxic chemotherapy in clinical treatment of cancer / Rajesh Thirumaran, George C. Prendergast, and Paul B. Gilman -- Targeted therapeutics in cancer treatment / Colin D. Weekes and Manuel Hidalgo -- Concepts in pharmacology and toxicology / Richard A. Westhouse and Bruce D. Car -- Cancer immunotherapy : challenges and opportunities / Andrew J. Lepisto, John R. McKolanis, and Olivera J. Finn -- Cancer vaccines / Freda K. Stevenson [and others].
505 0 ▼a Immunotherapy and cancer therapeutics : why partner? / Leisha A. Emens and Elizabeth M. Jaffee -- Immune stimulatory features of classical chemotherapy / Robbert G. van der Most, Anna K. Nowak, and Richard A. Lake -- Dendritic cells and coregulatory signals : immune checkpoint blockade to stimulate immunotherapy / Drew Pardoll -- Regulatory T cells in tumor immunity : role of toll-like receptors / Rong-Fu Wang -- Tumor-associated macrophages in cancer growth and progression / Alberto Mantovani, Paola Allavena, and Antonio Sica -- Tumor-associated myeloid-derived suppressor cells / Stephanie K. Bunt [and others] -- Programmed death ligand-1 and galectin-1 : pieces in the puzzle of tumor-immune escape / Gabriel A. Rabinovich and Thomas F. Gajewski -- Indoleamine 2,3-dioxygenase in immune escape : regulation and therapeutic inhibition / Alexander J. Muller and George C. Prendergast -- Arginase, nitric oxide synthase, and novel inhibitors of L-arginine metabolism in immune modulation / Susanna Mandruzzato, Simone Mocellin, and Vincenzo Bronte.
520 ▼a There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease. * Offers a synthesis of concepts that are useful to cancer immunologists and pharmacologists, who tend to work in disparate fields with little cross-communication * Drs Prendergast and Jaffee are internationally recognized leaders in cancer biology and immunology who have created a unique synthesis of fundamental and applied concepts in this important new area of cancer research * Summarizes the latest insights into how immune escape defines an essential trait of cancer * Includes numerous illustrations including: how molecular-targeted therapeutic drugs or traditional chemotherapy can be combined with immunotherapy to improve anti-tumor efficacy; and how reversing immune suppression by the tumor can cause tumor regression.
530 ▼a Issued also as a book.
538 ▼a Mode of access: World Wide Web.
650 0 ▼a Cancer ▼x Immunotherapy.
650 0 ▼a Antineoplastic agents ▼x Therapeutic use.
650 0 ▼a Tumors ▼x Immunological aspects.
650 2 ▼a Neoplasms ▼x therapy.
650 2 ▼a Antineoplastic Agents ▼x therapeutic use.
650 2 ▼a Immunotherapy ▼x methods.
700 1 ▼a Prendergast, George C.
700 1 ▼a Jaffee, Elizabeth M.
776 0 8 ▼i Print version: ▼t Cancer immunotherapy. ▼d Amsterdam ; Boston : Academic Press/Elsevier, 2007 ▼z 9780123725516 ▼z 0123725518 ▼w (211009) 000045782221
856 4 0 ▼3 ScienceDirect ▼u https://oca.korea.ac.kr/link.n2s?url=http://www.sciencedirect.com/science/book/9780123725516
945 ▼a KLPA
991 ▼a E-Book(소장)

소장정보

No. 소장처 청구기호 등록번호 도서상태 반납예정일 예약 서비스
No. 1 소장처 중앙도서관/e-Book 컬렉션/ 청구기호 CR 616.994061 등록번호 E14003490 도서상태 대출불가(열람가능) 반납예정일 예약 서비스 M

컨텐츠정보

목차

Contributors	p. xi
Part I	Principles of Cancer Immunobiology	
1	    Introduction   George C. Prendergast and Elizabeth M. Jaffee	p. 3
I	        Overview	p. 3
II	        Historical Background	p. 3
III	        Looking Ahead: Marrying Chemotherapy and Immunotherapy	p. 5
IV	        Parts of the Book	p. 6
        References	p. 8
        Further Reading	p. 8
2	    Cancer Immunoediting: From Immune Surveillance to Immune Escape   Ryungsa Kim	p. 9
I	        Introduction	p. 10
II	        Cancer Immune Surveillance	p. 10
III	        Cancer Immunoediting	p. 19
IV	        Concluding Remarks	p. 25
        References	p. 25
3	    Immunosurveillance: Innate and Adaptive Antitumor Immunity   Masahisa Jinushi and Glenn Dranoff	p. 29
I	        Introduction	p. 30
II	        Innate Antitumor Responses	p. 30
III	        Innate Immune Cells	p. 31
IV	        Adaptive Antitumor Responses	p. 33
V	        The Interplay of Innate and Adaptive Antitumor Immunity	p. 38
VI	        Conclusion	p. 39
        References	p. 39
4	    Cytokine Regulation of Immune Tolerance to Tumors   Ming O. Li and Richard A. Flavell	p. 43
I	        Introduction	p. 43
II	        Cytokine Regulation of Immune Tolerance to Tumors	p. 45
III	        Summary and Future Perspectives	p. 55
        References	p. 56
5	    Immunological Sculpting: Natural Killer Cell Receptors and Ligands   David A. Sallman and Julie Y. Djeu	p. 63
I	        Introduction	p. 64
II	        Activating Human NK Receptors	p. 65
III	        Inhibitory NK Receptors	p. 72
IV	        The Ly49 Receptor Family	p. 74
V	        Immunotherapy Approaches	p. 74
VI	        Conclusion	p. 77
        References	p. 78
        Further Reading	p. 80
6	    Immune Escape: Immunosuppressive Networks   Shuang Wei and Alfred Chang and Weiping Zou	p. 83
I	        Introduction	p. 83
II	        Imbalance Between Mature DCs and Immature DCs	p. 84
III	        Imbalance Between Stimulatory and Inhibitory B7 Family Molecules	p. 87
IV	        Imbalance Between Regulatory T Cells and Conventional T Cells	p. 90
V	        Concluding Remarks	p. 92
        References	p. 92
Part II	Cancer Therapeutics	
7	    Cytotoxic Chemotherapy in Clinical Treatment of Cancer   Rajesh Thirumaran and George C. Prendergast and Paul B. Gilman	p. 101
I	        Introduction	p. 101
II	        DNA-Damaging Agents	p. 103
III	        Antimetabolites	p. 109
IV	        Antimitotics	p. 112
V	        Chemotherapy Regimens	p. 113
        References	p. 115
        Useful Web Sites	p. 116
8	    Targeted Therapeutics in Cancer Treatment   Colin D. Weekes and Manuel Hidalgo	p. 117
I	        Introduction	p. 118
II	        Cell Cycle	p. 119
III	        The MAPK Family	p. 131
IV	        Challenges in the Clinical Development of Signal Transduction Inhibitors	p. 136
        References	p. 140
9	    Concepts in Pharmacology and Toxicology   Richard A. Westhouse and Bruce D. Car	p. 149
I	        Introduction	p. 150
II	        Concepts in Pharmacokinetics	p. 151
III	        Concepts in Toxicology	p. 159
IV	        Clinical Concerns for Pharmacology and Safety	p. 164
V	        Conclusion	p. 165
        References	p. 165
        Further Reading	p. 166
10	    Cancer Immunotherapy: Challenges and Opportunities   Andrew J. Lepisto and John R. McKolanis and Olivera J. Finn	p. 167
I	        Introduction	p. 168
II	        Prerequisites for Effective Cancer Immunotherapy: Identifying Tumor Antigens	p. 168
III	        Adoptive ("Passive") Immunotherapy	p. 169
IV	        Active-Specific Immunotherapy: Vaccines	p. 171
V	        Cancer-Induced Immunosuppression Impinges on Immunotherapy	p. 172
VI	        Cancer Immunotherapy in Mice Versus Humans	p. 175
VII	        Immunotherapy and Cancer Stem Cells	p. 176
VIII	        Autoimmunity Resulting from Cancer Immunotherapy	p. 176
IX	        Conclusion and Future Considerations	p. 177
        References	p. 178
11	    Cancer Vaccines   Freda K. Stevenson and Gianfranco Di Genova and Christian Ottensmeier and Natalia Savelyeva	p. 183
I	        Introduction	p. 184
II	        Tumor Antigens	p. 185
III	        Spontaneous Immunity to Cancer	p. 187
IV	        Toleragenic Pressure on Immunity to Cancer	p. 187
V	        Immune Responses to Conventional Vaccines	p. 189
VI	        Cancer Vaccine Strategies	p. 194
VII	        DNA Vaccines	p. 195
VIII	        Challenges of Translation to the Clinic	p. 199
IX	        Concluding Remarks	p. 200
        References	p. 200
        Further Reading	p. 204
Part III	Targets and Tactics to Improve Cancer Immunotherapy by Defeating Immune Suppression	
12	    Immunotherapy and Cancer Therapeutics: Why Partner?   Leisha A. Emens and Elizabeth M. Jaffee	p. 207
I	        Introduction: Why Immunotherapy for Cancer?	p. 208
II	        Immune Tolerance and Suppression: Multiple Layers of Negative Control	p. 209
III	        T Cell Activation: A Rheostat for Tuning Immune Responses	p. 212
IV	        Immune Modulation with Therapeutic Monoclonal Antibodies	p. 219
V	        Therapeutics that Mitigate the Influence of CD4[superscript +]CD25[superscript +] Tregs	p. 222
VI	        Endocrine and Biologically Targeted Therapy	p. 224
VII	        Conclusion	p. 225
        References	p. 225
13	    Immune Stimulatory Features of Classical Chemotherapy   Robbert G. van der Most and Anna K. Nowak and Richard A. Lake	p. 235
I	        Introduction	p. 236
II	        Tumor Cell Death	p. 236
III	        Pathways to Immunogenicity	p. 239
IV	        Chemotherapy and the Immune System	p. 243
V	        A Practical Partnership: Chemotherapy and Immunotherapy	p. 246
VI	        Effects of Chemotherapy on Human Antitumor Immunity and Chemoimmunotherapy Clinical Trials	p. 250
        References	p. 252
14	    Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy   Drew Pardoll	p. 257
I	        Regulation of T Cell Responses to Antigen	p. 258
II	        Regulatory T Cells	p. 261
III	        Immune Checkpoints in the Tumor Microenvironment	p. 262
IV	        Monoclonal Antibodies that Interfere with Coinhibitory Receptors on T Cells	p. 266
V	        What Is the Most Effective Way to Use Checkpoint Inhibitors?	p. 269
        References	p. 270
15	    Regulatory T Cells in Tumor Immunity: Role of Toll-Like Receptors   Rong-Fu Wang	p. 277
I	        Introduction	p. 278
II	        Immune Cells in Immunosurveillance and Tumor Destruction	p. 278
III	        TLRs and Their Signaling Pathways	p. 279
IV	        TLRs in Innate Immunity, Inflammation, and Cancer Development	p. 280
V	        Tumor-Infiltrating Immune Cells in the Tumor Microenvironment	p. 281
VI	        Molecular Marker for CD4[superscript +] Tregs	p. 282
VII	        Antigen Specificity of CD4[superscript +] Tregs	p. 282
VIII	        Suppressive Mechanisms of Tregs	p. 283
IX	        Functional Regulation of Tregs and Effector Cells by TLR Signaling	p. 283
X	        Implications for Enhancing Antitumor Immunity	p. 284
XI	        Conclusion	p. 285
        References	p. 285
16	    Tumor-Associated Macrophages in Cancer Growth and Progression   Alberto Mantovani and Paola Allavena and Antonio Sica	p. 289
I	        Introduction	p. 289
II	        Macrophage Polarization	p. 290
III	        Macrophage Recruitment at the Tumor Site	p. 291
IV	        Tam Expression of Selected M2 Protumoral Functions	p. 294
V	        Modulation of Adaptive Immunity by Tams	p. 296
VI	        Targeting Tams	p. 297
VII	        Concluding Remarks	p. 300
        References	p. 302
17	    Tumor-Associated Myeloid-Derived Suppressor Cells   Stephanie K. Bunt and Erica M. Hanson and Pratima Sinha and Minu K. Srivastava and Virginia K. Clements and Suzanne Ostrand-Rosenberg	p. 309
I	        Introduction	p. 310
II	        Multiple Suppressive Mechanisms that Contribute to Immunosuppression in Individuals with Tumors	p. 310
III	        MDSCs as a Key Cell Population that Mediates Tumor-Induced Immunosuppression	p. 311
IV	        MDSCs'' Use of Mechanisms to Mediate Effects on Multiple Target Cells	p. 317
V	        MDSC Induction by Tumor-Derived Cytokines and Growth Factors	p. 321
VI	        MDSC Linking of Inflammation and Tumor Progression	p. 322
VII	        Agents Responsible for Reducing MDSC Levels	p. 323
VIII	        Conclusions: Implications for Immunotherapy	p. 326
        References	p. 327
        Further Reading	p. 331
18	    Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor-Immune Escape   Gabriel A. Rabinovich and Thomas F. Gajewski	p. 333
I	        Programmed Death Ligand 1 and Programmed Death 1 Interactions	p. 334
II	        Galectin 1	p. 338
        References	p. 344
        Further Reading	p. 346
19	    Indoleamine 2,3-Dioxygenase in Immune Escape: Regulation and Therapeutic Inhibition   Alexander J. Muller and George C. Prendergast	p. 347
I	        Introduction	p. 348
II	        IDO Function in T Cell Regulation	p. 351
III	        Complex Control of IDO by Immune Regulatory Factors	p. 351
IV	        Immune Tolerance Via IDO in Dendritic Cells	p. 353
V	        IDO Dysregulation in Cancer Cells	p. 357
VI	        IDO as a Target for Therapeutic Intervention	p. 359
VII	        Discovery and Development of IDO Inhibitors	p. 360
VIII	        Conclusion	p. 361
        References	p. 362
        Further Reading	p. 368
20	    Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-Arginine Metabolism in Immune Modulation   Susanna Mandruzzato and Simone Mocellin and Vincenzo Bronte	p. 369
I	        Introduction	p. 370
II	        NOS: Genes, Regulation, and Activity	p. 371
III	        ARG: Genes, Regulation, and Activity	p. 372
IV	        Immunoregulatory Activities of ARG and NOS	p. 374
V	        Possible Physiological Role for L-ARG Metabolism in Immunity Control	p. 381
VI	        NOS in Cancer	p. 382
VII	        ARG in Cancer	p. 384
VIII	        ARG and NOS Inhibitors: A Novel Class of Immune Adjuvants?	p. 386
IX	        Conclusion and Perspectives	p. 388
        References	p. 389
        Further Reading	p. 399
Index	p. 401

관련분야 신착자료

WHO Classification of Tumours Editorial Board (2021)
대한가정의학회. 비만대사증후군연구회 (2021)
Stein, Ulrike S (2021)
Santiago-Cardona, Pedro G (2021)
Hargadon, Kristian M (2021)